单片复方制剂（STR）比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺（BIC/FTC/TAF）的临床药理学
Clinical pharmacology of the SingleTablet Regimen (STR) Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF).
作者信息
Di Perri Giovanni
机构信息
Infectious Diseases Clinical Unit, Dept. of Medical Sciences, University of Turin, Italy.
出版信息
Infez Med. 2023 Sep 1;31(3):283-289. doi: 10.53854/liim-3103-3. eCollection 2023.
Abstract
In Italy a proportion of HIV patients exceeding 50% are diagnosed at advanced stages of disease. A sizeable proportion of patients under chronic HIV treatment has a story of poor adherence with archived resistance associated mutations, a condition implying some risks in case of treatment with dual regimens. Conventional three-drug regimens will remain necessary in the short-mid term, in order to avoid treatment failure and selection of drug resistance. Efficacy, tolerability, safety, genetic barrier, forgiveness and a good compatibility with concurrent medications are all features that describe the overall quality of BIC/FTC/TAF, a combination whose robustness will remain a point of reference for the next years.
摘要
在意大利，超过50%的艾滋病病毒（HIV）患者在疾病晚期才被诊断出来。相当一部分接受慢性HIV治疗的患者有依从性差的病史，并伴有存档的耐药相关突变，这种情况意味着在使用双药方案治疗时存在一些风险。在短期至中期内，传统的三联药物方案仍将是必要的，以避免治疗失败和耐药性的产生。疗效、耐受性、安全性、基因屏障、宽容性以及与同时服用药物的良好兼容性，都是描述比克替拉韦/恩曲他滨/丙酚替诺福韦（BIC/FTC/TAF）组合整体质量的特征，该组合的稳健性在未来几年仍将是一个参考标准。
相似文献
1
Clinical pharmacology of the SingleTablet Regimen (STR) Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF).
Infez Med. 2023 Sep 1;31(3):283-289. doi: 10.53854/liim-3103-3. eCollection 2023.
2
The potential role of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) single-tablet regimen in the expanding spectrum of fixed-dose combination therapy for HIV.
HIV Med. 2020 Mar;21 Suppl 1:3-16. doi: 10.1111/hiv.12833.
3
Clinical pharmacology of the single tablet regimen bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF).
Infez Med. 2019 Dec 1;27(4):365-373.
4
Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United States.
Curr Med Res Opin. 2022 Feb;38(2):287-298. doi: 10.1080/03007995.2021.2007006. Epub 2021 Dec 7.
5
Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
J Antimicrob Chemother. 2019 Dec 1;74(12):3555-3564. doi: 10.1093/jac/dkz347.
6
Bioavailability of dissolved and crushed single tablets of bictegravir, emtricitabine, tenofovir alafenamide in healthy adults: the SOLUBIC randomized crossover study.
J Antimicrob Chemother. 2022 Dec 23;78(1):161-168. doi: 10.1093/jac/dkac369.
8
Utilization of bictegravir/emtricitabine/tenofovir alafenamide in patients with end-stage renal disease on hemodialysis.
Am J Health Syst Pharm. 2023 Apr 19;80(9):e92-e97. doi: 10.1093/ajhp/zxac339.
9
Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre.
J Antimicrob Chemother. 2022 Mar 31;77(4):1133-1139. doi: 10.1093/jac/dkab481.
10
Comparison of the design and methodology of Phase 3 clinical trials of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir-based dual therapy (DTG) in HIV: a systematic review of the literature.
Expert Rev Anti Infect Ther. 2023 Jan;21(1):65-76. doi: 10.1080/14787210.2023.2149490. Epub 2022 Nov 27.
引用本文的文献
1
Extending follow-up visits in people with HIV (PWH) receiving bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) therapy: an expert opinion.
Infez Med. 2025 Sep 1;33(3):268-278. doi: 10.53854/liim-3303-3. eCollection 2025.
2
Adherence and Cost-Utility Analysis of Antiretroviral Treatment in People Living with HIV in a Specialized Clinic in Mexico City.
Pharmacy (Basel). 2025 May 28;13(3):76. doi: 10.3390/pharmacy13030076.
3
Characteristics and factors associated with initial antiretroviral medicine use among newly treated HIV/AIDS patients in Zhejiang Province, Eastern China: A cross-sectional study.
Prev Med Rep. 2025 May 19;55:103114. doi: 10.1016/j.pmedr.2025.103114. eCollection 2025 Jul.
本文引用的文献
1
Long-acting antiretrovirals: a new era for the management and prevention of HIV infection.
J Antimicrob Chemother. 2022 Feb 2;77(2):290-302. doi: 10.1093/jac/dkab324.
2
Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/ tenofovir alafenamide vs. emtricitabine/ tenofovir disoproxil fumarate.
AIDS. 2021 Dec 1;35(15):2481-2487. doi: 10.1097/QAD.0000000000003062.
3
Long Dissociation of Bictegravir from HIV-1 Integrase-DNA Complexes.
Antimicrob Agents Chemother. 2023 May 1;65(5). doi: 10.1128/AAC.02406-20. Epub 2021 Mar 1.
4
Demographic and socio-economic determinants of poor HIV-risk perception at first HIV diagnosis: analysis of the HIV Surveillance data, Italy 2010-2016.
Ann Ist Super Sanita. 2020 Jul-Sep;56(3):267-276. doi: 10.4415/ANN_20_03_04.
5
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Lancet. 2020 Jul 25;396(10246):239-254. doi: 10.1016/S0140-6736(20)31065-5.
6
Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus.
Clin Infect Dis. 2021 Jul 15;73(2):e485-e493. doi: 10.1093/cid/ciaa988.
7
Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors: An Updated Review.
Clin Pharmacokinet. 2020 Sep;59(9):1085-1107. doi: 10.1007/s40262-020-00898-8.
8
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study.
Clin Infect Dis. 2020 Nov 5;71(8):1920-1929. doi: 10.1093/cid/ciz1243.
9
Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials.
J Acquir Immune Defic Syndr. 2020 Mar 1;83(3):310-318. doi: 10.1097/QAI.0000000000002275.
10
Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study.
HIV Res Clin Pract. 2019 Aug-Oct;20(4-5):111-122. doi: 10.1080/25787489.2019.1661696. Epub 2019 Sep 18.
Zotero 插件